Rebranding asymptomatic type 1 diabetes: the case for autoimmune beta cell disorder as a pathological and diagnostic entity
Year: 2016
Type: article
Abstract: The asymptomatic phase of type 1 diabetes is recognised by the presence of beta cell autoantibodies in the absence of hyperglycaemia. We propose that an accurate description of this stage is provided by the name 'Autoimmune Beta Cell Disorder' (ABCD). Specifically, we suggest that this nomenclature and diagnosis will, in a proactive manner, shift the paradigm towards type 1 diabetes being first and foremost an immune-mediated disease and only later a metabolic disease, presaging more active therapeutic intervention in the asymptomatic stage of disease, before end-stage beta cell failure. Furthermore, we argue that accepting ABCD as a diagnosis will be critical in order to accelerate pharmaceutical, academic and public activities leading to clinical trials that could reverse beta cell autoimmunity and halt progression to symptomatic insulin-requiring type 1 diabetes. We recognize that there are both opportunities and challenges in the implementation of the ABCD concept but hope that the notion of 'asymptomatic autoimmune disease' as a disorder will be widely discussed and eventually accepted.
Source: Diabetologia
Institutions: Paul Langerhans Institute Dresden, Center for Regenerative Therapies Dresden, Technische Universität Dresden, Universitair Ziekenhuis Leuven, University of Washington, Benaroya Research Institute, TUM Klinikum, Helmholtz Munich, Institute of Diabetes Research, Technical University of Munich, T1D Exchange, University of Florida, The University of Melbourne, Walter and Eliza Hall Institute of Medical Research, University of California, San Francisco, Baylor College of Medicine, Colorado School of Public Health, University of Colorado Anschutz, King's College London, Vanderbilt University, VA Tennessee Valley Healthcare System, University of Cambridge, National Institute for Health and Care Research, NIHR Cambridge Biomedical Research Centre, Wellcome Trust
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $3,490
OpenAlex ID: W2542367907